stockrow
Friday 6 November 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
14.86
0.33
+2.27%
Follow RDY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 4 | 4 |
+8 more TTM periods Free account |
| 6.60% | 8.21% | 11.40% | 16.28% | ||
| 4.44% | 5.55% | 7.63% | 10.88% | ||
ROIC |
4.77% | 5.89% | 8.55% | 11.88% | |
Return on Tangible Assets |
9.98% | 12.38% | 17.09% | 22.80% | |
Average Days of Receivables |
115.83 | 112.81 | 110.01 | 106.53 | |
Free Cash Flow per Share |
0.12 | 0.18 | 0.26 | 0.35 | |
Free Cash Flow |
96.00 | 139.00 | 215.00 | 288.00 | |
Capital Expenditures |
(217.00) | (287.00) | (392.00) | (429.00) | |
| Other line items | |||||
Cash ROIC |
1.71% | 2.43% | 3.70% | 4.91% | |
Accounts Receivable Turnover |
3.09 | 3.16 | 3.35 | 3.54 | |
Accounts Payable Turnover |
4.08 | 4.12 | 4.38 | 4.03 | |
Inventory Turnover |
1.99 | 1.98 | 2.05 | 2.06 | |
Average Days of Payables |
81.19 | 84.13 | 76.84 | 93.93 | |
Days of Inventory on Hand |
182.41 | 180.59 | 176.13 | 181.86 | |
Tax Rate |
(0.21) | (0.21) | (0.23) | (0.23) | |
Research and Development Expense of Revenue |
6.83% | 7.10% | 7.15% | 7.47% | |
Selling, General and Administrative Expense of Revenue |
33.98% | 33.24% | 31.76% | 29.80% | |
Share Based Compensation of Revenue |
0.09% | 0.09% | 0.08% | 0.10% | |
Interest Coverage |
6.57 | 8.52 | 13.48 | 19.90 | |
Operating CF/Net income |
1.16 | 1.26 | 1.33 | 1.11 | |
Depreciation/Fixed assets |
0.18 | 0.18 | 0.18 | 0.17 | |
Capex/Depreciation |
(0.99) | (1.30) | (1.78) | (1.94) | |
Revenue per Share |
4.00 | 4.39 | 4.30 | 4.73 | |
Operating CF per Share |
0.38 | 0.54 | 0.73 | 0.86 | |
Capex per Share |
(0.26) | (0.37) | (0.47) | (0.52) | |
Capex to Sales |
0.07 | 0.08 | 0.11 | 0.11 |
Columns are period end dates · fundamentals updated 2 Nov 2026